Samuel Heck, DO
Family Medicine · Wichita, KSNPI 1346207370
Payments from drug & device makers
Across 65 payments — averaging $13.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$285
- AstraZeneca$169
- Lilly USA, LLC$113
- Takeda Pharmaceuticals U.S.A., Inc.$39
- AbbVie$38
- Radius Health, Inc.$35
- plus $186 from 8 others
What the payments were for
- Food & beverage$864100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $285 |
| AstraZeneca | 3 | $169 |
| Lilly USA, LLC | 16 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $39 |
| AbbVie(2 entities) | 3 | $38 |
| Radius Health, Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $34 |
| Merck | 3 | $33 |
| Amgen | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| GSK | 2 | $23 |
| Amarin Pharma, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$125
How this compares
$864 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $79,324 |
| CreonLipase/Protease/Amylase | 13 | $72,569 |
| JardianceEmpagliflozin | 44 | $44,791 |
| JanuviaSitagliptin Phosphate | 23 | $31,180 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $17,367 |
| LinzessLinaclotide | 20 | $16,266 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,156 |
| MyrbetriqMirabegron | 12 | $12,788 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $12,028 |
| FarxigaDapagliflozin Propanediol | 19 | $10,355 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,736 |
| BelsomraSuvorexant | 12 | $5,234 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,065 |
| Duloxetine Hcl | 88 | $2,695 |
| SynthroidLevothyroxine Sodium | 19 | $2,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Synthroid | $38 | $91,47652 claims |
| Boehringer IngelheimJardiance | $12 | $44,79144 claims |
| MerckJanuvia, Janumet, Belsomra | $33 | $43,15047 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $23 | $42,55166 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $12,78812 claims |
| AstraZenecaFarxiga | $169 | $10,35519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Terry PolingWichita$24.2M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Brandon AllemanWichita$3M
- Tracy KleinWichita$2.7M
- William SimonWichita$1.1M
- Tana GoeringWichita$1.1M
- Gregory LakinWichita$897K
- Timothy KoehlerWichita$675K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.